喉癌组织中Survivin、MMP—2的表达、临床意义及相关性研究(3)
[8] 董文荣，李晓明.凋亡抑制蛋白Survivin在肿瘤诊断与治疗中的价值[J].疑难病杂志，2006，5(5)：397-397.
[9] Kato J，Kuwabara Y，Mitani M，et al.Expression of surviving in esophageal cancer：correlation with the prognosis and response to chemotherapy[J].Int Cancer，2001，95(2)：92-95.
[10] 朱瑾，徐如君，吴正虎，等.喉鳞状细胞癌组织中Survivin基因与p15和p16基因表达的关系[J].中华耳鼻咽喉科杂志，2004，39(6)：356-359.
[11] 王吉喆，关超，王寿忱，等.Survivin蛋白在喉鳞状细胞癌中的表达及意义[J].临床耳鼻喉科杂志，2005，19(6)：247-249.
[12] Fang J，Shing Y，Wiederschain D，et al.Matrixmetalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model[J].Proc Natl Acad Sci USA，2000，97(8)：3884-3889.
[13] Brinckerhoff CE，Rutter JL，Benbow U.Interstitial collagenases as markers of tumor progression[J].Clin Cancer Res，2000，6(12)：4823-4830.
[14] Vilaha A，Sahuquillo J，Poca MA.Matrix metaloproteinases in neumlogical brain lesions：a new therapeutic target[J].Rev Neural，2010，51(2)：95-107.
[15] Juan C，Manuel F，Lucas V，et al.Expression and clinical signifcance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carci-noma[J].Oral Oncol，2005，41(3)：283-293.
[16] Das S，Mandal M，Chakraborti T，et al.Structure and evolutionary aspects of matrix metalloproteinases：A brief overview[J].Mol Cell Biochem，2003，253(1-2)：31-40.
[17] 王晓茜，山艳春，王继群，等.基质金属蛋白酶-2在喉鳞状细胞癌中的表达及临床意义[J].临床耳鼻咽喉科杂志，2006，20(24)：1109-1110.
[18] Bogusiewicz M，Stryjecka-Zimmer M，Szymanski M，et al.Activity of matrix metalloproteinase-2 and -9 in advanced laryngeal cancer[J].Otolaryngol Head Neck Surg，2003，128(1)：132-136.
[19] Gorogh T，Beieru H，Baumken J，et al.Metallo-proteinases and their inhibitors：Influence on tumor invasiveness and metastasis formation in head and neck squarnous cell carcinomas[J].Head Neck，2006，28(1)：31-39.
[20] Krecicki T，Zalesska-Krecicka M，Jelen M，et al.Expression of type Ⅳ collagen and matrix metalloproteinase-2(typeⅣ collagenase) in relation to nodal status in laryngeal cancer[J].Clin Otolaryngol Allied Sci，2001，26(6)：469-472.
(收稿日期：2014-09-25 本文编辑：郭静娟) (吴春芳 李海洲 李富)
[9] Kato J，Kuwabara Y，Mitani M，et al.Expression of surviving in esophageal cancer：correlation with the prognosis and response to chemotherapy[J].Int Cancer，2001，95(2)：92-95.
[10] 朱瑾，徐如君，吴正虎，等.喉鳞状细胞癌组织中Survivin基因与p15和p16基因表达的关系[J].中华耳鼻咽喉科杂志，2004，39(6)：356-359.
[11] 王吉喆，关超，王寿忱，等.Survivin蛋白在喉鳞状细胞癌中的表达及意义[J].临床耳鼻喉科杂志，2005，19(6)：247-249.
[12] Fang J，Shing Y，Wiederschain D，et al.Matrixmetalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model[J].Proc Natl Acad Sci USA，2000，97(8)：3884-3889.
[13] Brinckerhoff CE，Rutter JL，Benbow U.Interstitial collagenases as markers of tumor progression[J].Clin Cancer Res，2000，6(12)：4823-4830.
[14] Vilaha A，Sahuquillo J，Poca MA.Matrix metaloproteinases in neumlogical brain lesions：a new therapeutic target[J].Rev Neural，2010，51(2)：95-107.
[15] Juan C，Manuel F，Lucas V，et al.Expression and clinical signifcance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carci-noma[J].Oral Oncol，2005，41(3)：283-293.
[16] Das S，Mandal M，Chakraborti T，et al.Structure and evolutionary aspects of matrix metalloproteinases：A brief overview[J].Mol Cell Biochem，2003，253(1-2)：31-40.
[17] 王晓茜，山艳春，王继群，等.基质金属蛋白酶-2在喉鳞状细胞癌中的表达及临床意义[J].临床耳鼻咽喉科杂志，2006，20(24)：1109-1110.
[18] Bogusiewicz M，Stryjecka-Zimmer M，Szymanski M，et al.Activity of matrix metalloproteinase-2 and -9 in advanced laryngeal cancer[J].Otolaryngol Head Neck Surg，2003，128(1)：132-136.
[19] Gorogh T，Beieru H，Baumken J，et al.Metallo-proteinases and their inhibitors：Influence on tumor invasiveness and metastasis formation in head and neck squarnous cell carcinomas[J].Head Neck，2006，28(1)：31-39.
[20] Krecicki T，Zalesska-Krecicka M，Jelen M，et al.Expression of type Ⅳ collagen and matrix metalloproteinase-2(typeⅣ collagenase) in relation to nodal status in laryngeal cancer[J].Clin Otolaryngol Allied Sci，2001，26(6)：469-472.
(收稿日期：2014-09-25 本文编辑：郭静娟) (吴春芳 李海洲 李富)